Search Results

GPCR name (including misspells and variations) as a sub-domain or sub-folder.

Institute of Medical Research, Deputy Director of the Australian Research Council Centre for Personalised Therapeutics

Brian Collier in the Department of Pharmacology and Therapeutics at McGill University (1994).

Michael Feigin is an Associate Professor in the Department of Pharmacology and Therapeutics, and Director of Graduate Studies of Experimental Therapeutics at Roswell Park Comprehensive Cancer Center in Buffalo disrupting histone processing on rapidly proliferating cells, such as cancer cells, and suggested a therapeutic

protein-coupled receptors (GPCRs) regulate motivated behavior and how these receptors can be targeted for therapeutic distinct signaling pathways with their physiological effects and may serve as the basis for more selective therapeutics

Brian Collier in the Department of Pharmacology and Therapeutics at McGill University (1994).

nanobodies as research tools, to investigate different GPCR conformations, while also focusing on their therapeutic

Yamina will schedule a future talk with Jacek about GPCRs as therapeutic modalities. The discussion revealed their interest in GPCRs as therapeutic modalities and possible future collaborations

receptors would be a significant breakthrough in cardiovascular biology as they could be targeted for therapeutic

neuronal circuits — insights that inform next-generation functional assay development and translational therapeutic

of Canada (2014), the Julie Axelrod award from the American Society of Pharmacology and Exerimental Therapeutics

GPCRs in the regulation of physiologic/pathologic function in the heart in an effort to uncover novel therapeutic

Award and the Goodman and Gilman Award from the American Society for Pharmacology and Experimental Therapeutics Institute, highlighting its translational approach to research and its capacity to translate research into therapeutic

Award and the Goodman and Gilman Award from the American Society for Pharmacology and Experimental Therapeutics Institute, highlighting its translational approach to research and its capacity to translate research into therapeutic

Terry Kenakin’s unique course, Development of GPCR Ligands as Therapeutic Drugs , and gain essential signaling and drug discovery Symposium & Workshop - Brazil NEW April 1 - 3, 2025 | 2nd Peptide-Based Therapeutics Summit - USA April 2 - 3, 2025 | New therapeutic modalities: Transforming receptor pharmacology - UK Australia GPCR Jobs NEW Open Postdoctoral position - Stanford University Structural Biologist - Confo Therapeutics Pharmacologist - Schrödinger Scientist - Biology - Superluminal Medicines Scientist I Cell Biology - Tectonic Therapeutic

Sep 20, 2022 — First contributor article published: Therapeutic validation of an orphan G protein‐coupled

. 🗓️ Upcoming 4-Week Course: Development of GPCR Ligands as Therapeutic Drugs starting March 20 – April biotechs public Aikium's AI-Driven mRNA Engine Looks to Address Undruggable Disordered Proteins Tectonic Therapeutic - 21, 2025 | 2nd GPCR signaling and drug discovery Symposium & Workshop NEW April 2 - 3, 2025 | New therapeutic PhD Position GPCR Molecular Pharmacologist Scientist - Biology Scientist I Cell Biology - Tectonic Therapeutic

Optimization of Candidate Molecules GPCRs have been and arguably still are the most prolific and fertile therapeutic

analysis, revealed nuanced roles of RGS4, RGS9, and RGSZ — not just as modulators but as potential therapeutic

Clements' work is primarily focused on translational developments of small molecule therapeutics, and

This could accelerate discovery of therapeutic targets by combining multiplex data with focused downstream

Clear Platform Assessment: Gain rapid, independent insight into GPCR platform risks and true therapeutic

Whether you’re decoding signaling pathways or designing the next generation of therapeutics, Revvity

. 💊 Therapeutic Potential : Understanding bias enables researchers to design drugs that target specific Kenakin challenges the traditional approach and encourages leveraging bias for better therapeutic outcomes